CY1111576T1 - Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps) - Google Patents

Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps)

Info

Publication number
CY1111576T1
CY1111576T1 CY20111100576T CY111100576T CY1111576T1 CY 1111576 T1 CY1111576 T1 CY 1111576T1 CY 20111100576 T CY20111100576 T CY 20111100576T CY 111100576 T CY111100576 T CY 111100576T CY 1111576 T1 CY1111576 T1 CY 1111576T1
Authority
CY
Cyprus
Prior art keywords
amide derivatives
substituted methylene
methylene amide
ptps
present
Prior art date
Application number
CY20111100576T
Other languages
English (en)
Inventor
Dominique Swinnen
Agnès Bombrun
Jerôme GONZALEZ
Patrick Gerber
Pierre-André Pittet
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1111576T1 publication Critical patent/CY1111576T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Η παρούσα εφεύρεση αναφέρεται σε υποκατεστημένα παράγωγα μεθυλένο αμίδης του χημικού τύπου (I) και στη χρήση αυτών στην αντιμετώπιση και/ή στη πρόληψη μεταβολικών διαταραχών που μεσολαβούνται από την αντοχή στην ινσουλίνη ή την υπεργλυκαιμία, που περιλαμβάνουν το σακχαρώδη διαβήτη τύπου I και/ή II, τη διαταραγμένη ανοχή στη γλυκόζη, την αντοχή στην ινσουλίνη, την υπερλιπιδαιμία, την υπερτριγλυκεριδαιμία, την υπερχοληστερολαιμία, τη παχυσαρκία, το σύνδρομο πολυκυστικών ωοθηκών (PCOS). Συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται στη χρήση των υποκατεστημένων παραγώγων μεθυλένο αμίδης του χημικού τύπου (I) για τη ρύθμιση, ιδιαιτέρως την αναστολή της δραστηριότητας των PTPs. Επίσης η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο αντιμετώπισης του διαβήτη τύπου II, της παχυσαρκίας και ρύθμισης της όρεξης στα θηλαστικά. Η παρούσα εφεύρεση αναφέρεται επιπλέον σε καινοτόμα υποκατεστημένα παράγωγα μεθυλένο αμίδης και στη μέθοδο παρασκευής αυτών. Χημικός τύπος (I).
CY20111100576T 2002-01-29 2011-06-16 Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps) CY1111576T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02100078 2002-01-29
EP02100410 2002-04-25
EP03734697A EP1470102B1 (en) 2002-01-29 2003-01-27 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)

Publications (1)

Publication Number Publication Date
CY1111576T1 true CY1111576T1 (el) 2015-10-07

Family

ID=27664997

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100576T CY1111576T1 (el) 2002-01-29 2011-06-16 Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps)

Country Status (24)

Country Link
US (1) US7592477B2 (el)
EP (1) EP1470102B1 (el)
JP (2) JP4828793B2 (el)
KR (1) KR100922041B1 (el)
CN (1) CN100410236C (el)
AT (1) ATE510817T1 (el)
AU (1) AU2003239296B2 (el)
BR (1) BR0307394A (el)
CA (1) CA2472021C (el)
CY (1) CY1111576T1 (el)
DK (1) DK1470102T3 (el)
EA (1) EA012260B1 (el)
HK (1) HK1073649A1 (el)
HR (1) HRP20040612A2 (el)
IL (1) IL163144A (el)
MX (1) MXPA04007253A (el)
NO (1) NO329742B1 (el)
PL (1) PL207295B1 (el)
PT (1) PT1470102E (el)
RS (1) RS51865B (el)
SI (1) SI1470102T1 (el)
UA (1) UA82661C2 (el)
WO (1) WO2003064376A1 (el)
ZA (1) ZA200405179B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1656139E (pt) * 2003-07-21 2011-11-04 Merck Serono Sa Arildicarboxamidas
WO2005012280A1 (en) * 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides
ATE381529T1 (de) 2003-10-13 2008-01-15 Serono Lab Verfahren zur herstellung von para-phenylalkynyl benzaldehyden
EA011811B1 (ru) * 2004-02-27 2009-06-30 Лаборатуар Сероно Са Применение производных метиленамида при лечении сердечно-сосудистых нарушений
AU2005231980B2 (en) * 2004-04-07 2011-09-08 Merck Serono Sa 1,1'-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors
CN1942428A (zh) 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2007009959A1 (en) * 2005-07-15 2007-01-25 Laboratoires Serono S.A. Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5773560B2 (ja) 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｅｔｐ阻害剤のポリマー製剤
JP2009526773A (ja) * 2006-02-13 2009-07-23 ラボラトワール セローノ ソシエテ アノニム 細菌感染症治療のためのスルホンアミド誘導体
WO2008044731A1 (fr) * 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Dérivé d'acide n-phényloxamidique
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2602839A1 (en) 2010-08-05 2013-06-12 Idemitsu Kosan Co., Ltd. Organic electroluminescent element
CN102512407B (zh) * 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
EP2917194B1 (en) * 2012-11-06 2017-09-27 Eli Lilly and Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
US10647664B2 (en) * 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
JP7454573B2 (ja) * 2018-11-23 2024-03-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用
CN115297860A (zh) * 2020-04-06 2022-11-04 普渡研究基金会 新型n-芳基草氨酸
CN114478522B (zh) * 2022-01-25 2023-07-28 山东大学 一种吡啶并咪唑类衍生物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217482A (en) * 1975-07-25 1977-02-09 Sumitomo Chem Co Ltd Preparation of quinazolinone derivatives
AU641052B2 (en) * 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
ATE233240T1 (de) 1994-12-02 2003-03-15 Yamanouchi Pharma Co Ltd Neues amidinonaphthylderivat oder dessen salz
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JP3283485B2 (ja) * 1998-04-10 2002-05-20 日本たばこ産業株式会社 アミジン化合物
US6488973B1 (en) * 1998-10-05 2002-12-03 Food Talk, Inc. Method of making a cooking pouch containing a raw protein portion, a raw or blanched vegetable portion and a sauce
EP1123928A4 (en) * 1998-10-20 2005-02-16 Takeda Pharmaceutical 1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICAMENT
JP2003509429A (ja) * 1999-09-10 2003-03-11 ノボ ノルディスク アクティーゼルスカブ タンパク質チロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター
WO2002018321A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
WO2002100396A1 (en) 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
EA011811B1 (ru) * 2004-02-27 2009-06-30 Лаборатуар Сероно Са Применение производных метиленамида при лечении сердечно-сосудистых нарушений

Also Published As

Publication number Publication date
RS51865B (sr) 2012-02-29
KR100922041B1 (ko) 2009-10-19
CA2472021C (en) 2012-08-14
BR0307394A (pt) 2004-11-09
IL163144A (en) 2012-07-31
US7592477B2 (en) 2009-09-22
ATE510817T1 (de) 2011-06-15
NO20043520L (no) 2004-10-05
DK1470102T3 (da) 2011-06-20
ZA200405179B (en) 2005-08-31
CN100410236C (zh) 2008-08-13
EA200400882A1 (ru) 2005-04-28
WO2003064376A1 (en) 2003-08-07
NO329742B1 (no) 2010-12-13
EA012260B1 (ru) 2009-08-28
EP1470102A1 (en) 2004-10-27
MXPA04007253A (es) 2004-10-29
KR20040104953A (ko) 2004-12-13
SI1470102T1 (sl) 2011-08-31
PL371198A1 (en) 2005-06-13
CN1633410A (zh) 2005-06-29
HK1073649A1 (en) 2005-10-14
JP2011256174A (ja) 2011-12-22
PL207295B1 (pl) 2010-11-30
US20050124656A1 (en) 2005-06-09
AU2003239296B2 (en) 2008-10-23
HRP20040612A2 (en) 2005-04-30
JP4828793B2 (ja) 2011-11-30
EP1470102B1 (en) 2011-05-25
UA82661C2 (uk) 2008-05-12
JP2005516061A (ja) 2005-06-02
PT1470102E (pt) 2011-06-06
CA2472021A1 (en) 2003-08-07
RS65304A (en) 2007-02-05

Similar Documents

Publication Publication Date Title
CY1111576T1 (el) Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps)
EA200601869A1 (ru) Карбоновые кислоты
UA84390C2 (ru) Производные амидов как активаторы глюкокиназы
CY1114660T1 (el) ΠΑΡΑΓΩΓΑ 2-ΑΔΑΜΑΝΤΥΛΟΥΡΙΑΣ ΩΣ ΕΚΛΕΚΤΙΚΟΙ ΑΝΑΣΤΟΛΕΙΣ 11β-HSD1
BR0313266A (pt) Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
EA200870471A1 (ru) Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
EA200600240A1 (ru) Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением матеболизма
EA200870489A1 (ru) Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
HK1098125A1 (en) Indane acetic acid compounds
EA200870462A1 (ru) Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
BRPI0507481A (pt) composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
WO2007041077A3 (en) Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
EA199900669A1 (ru) Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
EP1794120A4 (en) peptidase
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
RS20050594A (en) 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização